Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia

References

• Dohner H, Weisdorf DJ, Bloomfield CD, et al. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. doi: 10.1056/NEJMra1406184
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Altman JK, Assi R, et al. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(5):503–513. doi: 10.6004/jnccn.2023.0025
   PubMed Web of Science ®Google Scholar
• Surveillance. Epidemiology, and end results program (SEER). Cancer stat facts: leukemia — acute myeloid leukemia (AML). 2023. [cited 2023 May 12]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html
   Google Scholar
• De Kouchkovsky I, Abdul-Hay M. ‘Acute myeloid leukemia: a comprehensive review and 2016 update’. Blood Cancer J. 2016;6(7):e441. doi: 10.1038/bcj.2016.50
   PubMed Web of Science ®Google Scholar
• Yi M, Li A, Zhou L, et al. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1):72. doi: 10.1186/s13045-020-00908-z
   PubMed Web of Science ®Google Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–1924. doi: 10.3324/haematol.2012.066100
   PubMed Web of Science ®Google Scholar
• Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014;15(9):e382–94. doi: 10.1016/S1470-2045(14)70008-7
   PubMed Web of Science ®Google Scholar
• Martens JH, Stunnenberg HG. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett. 2010;584(12):2662–2669. doi: 10.1016/j.febslet.2010.04.002
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461). Blood. 2002;100(13):4325–4336. doi: 10.1182/blood-2002-03-0772
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–1377. doi: 10.1182/blood.2022016867
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi: 10.1038/s41375-022-01613-1
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Maciejewski JP, Wilmink JW, et al. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene. 2018;37(15):1949–1960. doi: 10.1038/s41388-017-0077-z
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058–1066. doi: 10.1056/NEJMoa0903840
   PubMed Web of Science ®Google Scholar
• Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a Neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–234. doi: 10.1016/j.ccr.2010.01.020
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567. doi: 10.1016/j.ccr.2010.11.015
   PubMed Web of Science ®Google Scholar
• Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339–344. doi: 10.1084/jem.20092506
   PubMed Web of Science ®Google Scholar
• Venugopal S, Watts JM. Olutasidenib: from bench to bedside. Blood Adv. 2023;7(16):4358–4365. doi: 10.1182/bloodadvances.2023009854
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732–736. doi: 10.1002/ajh.24072
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi: 10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Sargas C, Ayala R, Chillón MC, et al. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. Haematologica. 2021;106(12):3079–3089. doi: 10.3324/haematol.2020.263806
   PubMed Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636–3643. doi: 10.1200/JCO.2010.28.3762
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010;28(14):2348–2355. doi: 10.1200/JCO.2009.27.3730
   PubMed Web of Science ®Google Scholar
• Duchmann M, Micol JB, Duployez N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021;137(20):2827–2837. doi: 10.1182/blood.2020010165
   PubMed Web of Science ®Google Scholar
• DiNardo C, de Botton S, Pollyea DA, et al. Molecular profiling and relationship with clinical response in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class potent inhibitor of mutant IDH1, in addition to data from the completed dose escalation portion of the phase 1 study [abstract]. Blood. 2015;126:1306. doi: 10.1182/blood-2015-07-657908
   Google Scholar
• Thol F, Damm F, Wagner K, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2010;116(4):614–616. doi: 10.1182/blood-2010-03-272146
   PubMed Web of Science ®Google Scholar
• Choe S, Wang H, DiNardo CD, et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020;4(9):1894–1905. doi: 10.1182/bloodadvances.2020001503
   PubMed Web of Science ®Google Scholar
• Pollyea DA, DiNardo CD, Arellano ML, et al. Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations. Clin Cancer Res. 2022;28(13):2753–2761. doi: 10.1158/1078-0432.CCR-21-3467
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744. doi: 10.1038/nature08617
   PubMed Web of Science ®Google Scholar
• McMurry H, Fletcher L, Traer E. IDH inhibitors in AML—promise and pitfalls. Curr Hematol Malig Rep. 2021;16(2):207–217. doi: 10.1007/s11899-021-00619-3
   PubMed Web of Science ®Google Scholar
• Roloff GW, Odenike O, Bajel A, et al. Contemporary approach to acute myeloid leukemia therapy in 2022. Am Soc Clin Oncol Educ Book. 2022;42(42):568–583. doi: 10.1200/EDBK_349605
   Google Scholar
• Celgene Corporation. IDHIFA® (enasidenib) tablets, for oral use [prescribing information]. Summit (NJ): Celgene Corporation; 2017.
   Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398. doi: 10.1056/NEJMoa1716984
   PubMed Web of Science ®Google Scholar
• Rigel Pharmaceuticals, Inc. REZLIDHIA™ (olutasidenib) capsules, for oral use [prescribing information]. Rigel Pharmaceuticals Inc.; 2022. South San Francisco (CA).
   Google Scholar
• Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386:1519–1531. doi: 10.1056/NEJMoa2117344
   PubMed Web of Science ®Google Scholar
• Servier Pharmaceuticals LLC. TIBSOVO® (ivosidenib tablets), for oral use [prescribing information]. Boston (MA): Servier Pharmaceuticals LLC; 2023.
   Google Scholar
• Heuser M, Palmisiano N, Mantzaris I, et al. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia. 2020;34(11):2903–2913. doi: 10.1038/s41375-020-0996-5
   PubMed Web of Science ®Google Scholar
• Sulkowski PL, Corso CD, Robinson ND, et al. 2-hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9(375). doi: 10.1126/scitranslmed.aal2463
   PubMed Web of Science ®Google Scholar
• Caravella JA, Lin J, Diebold RB, et al. Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor. J Med Chem. 2020;63(4):1612–1623. doi: 10.1021/acs.jmedchem.9b01423
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Fathi AT, DiNardo CD, et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31(2):272–281. doi: 10.1038/leu.2016.275
   PubMed Web of Science ®Google Scholar
• Reinbold R, Hvinden IC, Rabe P, et al. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. Nat Commun. 2022;13(1):4785. doi: 10.1038/s41467-022-32436-4
   PubMed Web of Science ®Google Scholar
• Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300–305. doi: 10.1021/acsmedchemlett.7b00421
   PubMed Web of Science ®Google Scholar
• Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023;10(1):e46–e58. doi: 10.1016/S2352-3026(22)00292-7
   PubMed Web of Science ®Google Scholar
• de Botton S, Fenaux P, Yee KWL, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023;7(13):3117–3127. doi: 10.1182/bloodadvances.2022009411
   PubMed Web of Science ®Google Scholar
• Cortes J, Jurcic J, Baer MR, et al. Olutasidenib for the treatment of mIDH1 acute myeloid leukemia in patients relapsed or refractory to hematopoietic stem cell transplant, prior mIDH1 inhibitor, or venetoclax [poster]. In: Presented at the American Society of Hematology Annual Meeting, December 9-12, 2023; San Diego, California, USA.
   Google Scholar
• Khanna V, Azenkot T, Liu SQ, et al. Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: a multicenter retrospective analysis. Leuk Res. 2023;131:107331. doi: 10.1016/j.leukres.2023.107331
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Shallis RM, Derkach A, et al. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. Leuk Res. 2022;122:106942. doi: 10.1016/j.leukres.2022.106942
   PubMed Web of Science ®Google Scholar